 <h1>Nesina Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>alogliptin</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about alogliptin. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Nesina.</p><h2>In Summary</h2><p><b>More frequent side effects include:</b> upper respiratory tract infection, headache, and nasopharyngitis.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to alogliptin: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, alogliptin (the active ingredient contained in Nesina) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking alogliptin:</p><p>
<i>More common</i>
</p><ul>
<li>Anxiety</li>
<li>blurred vision</li>
<li>chills</li>
<li>cold sweats</li>
<li>coma</li>
<li>confusion</li>
<li>cool, pale skin</li>
<li>depression</li>
<li>dizziness</li>
<li>fast heartbeat</li>
<li>headache</li>
<li>increased hunger</li>
<li>nausea</li>
<li>nightmares</li>
<li>seizures</li>
<li>shakiness</li>
<li>slurred speech</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Chest pain</li>
<li>decreased urine output</li>
<li>dilated neck veins</li>
<li>extreme fatigue</li>
<li>irregular breathing</li>
<li>irregular heartbeat</li>
<li>swelling of the face, fingers, feet, or lower legs</li>
<li>tightness in chest</li>
<li>troubled breathing</li>
<li>weight gain</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Blistering, peeling, or loosening of the skin</li>
<li>bloating</li>
<li>constipation</li>
<li>cough</li>
<li>dark-colored urine</li>
<li>diarrhea</li>
<li>difficulty with swallowing</li>
<li>feeling of discomfort</li>
<li>fever</li>
<li>general feeling of tiredness or weakness</li>
<li>headache</li>
<li>hives, itching, or rash</li>
<li>indigestion</li>
<li>inflammation of the joints</li>
<li>joint or muscle pain</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>light-colored stools</li>
<li>loss of appetite</li>
<li>muscle aches</li>
<li>pains in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots in the mouth or on the lips</li>
<li>stomach pain, continuing</li>
<li>swollen lymph glands</li>
<li>tightness in the chest</li>
<li>vomiting</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Redness of the skin</li>
<li>severe joint pain</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of alogliptin may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Body aches or pain</li>
<li>ear congestion</li>
<li>loss of voice</li>
<li>sneezing</li>
<li>stuffy or runny nose</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to alogliptin: oral tablet</i></p><h3>General</h3><p>The most frequently reported side effects included nasopharyngitis, headache, and upper respiratory tract infection.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>During clinical trials, acute pancreatitis was reported in 6 (0.2%) patients receiving 25 mg and 2 patients (less than 0.1%) who were treated with active comparators or placebo.  In a cardiovascular outcome trial of patient with high cardiovascular risk, acute pancreatitis was reported in 10 patients receiving this drug and 7 patients receiving placebo (0.4% vs 0.3%).<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Abdominal pain, gastroesophageal reflux disease</p>
<p><b>Uncommon</b> (0.1% to 1%): Pancreatitis </p>
<p><b>Postmarketing reports</b>: Acute pancreatitis, diarrhea, constipation, nausea, ileus<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Frequency not reported</b>: Arthralgia<sup>[Ref]</sup></p><p>Between October 2006 and December 2013, thirty-three cases of severe arthralgia have been reported to the FDA Adverse Event Reporting System Database.  Each case involved the use of 1 or more dipeptidyl peptidase-4 (DPP-4) inhibitor.  In all cases, substantial reduction in prior activity level was reported, 10 patients were hospitalized due to disabling joint pain.  In 22 cases, symptoms appeared within 1 month of starting therapy, in 23 cases symptoms resolved less than 1 month after discontinuation.  A positive rechallenge was reported in 8 cases, with 6 cases involving use of a different DPP-4 inhibitor.  Sitagliptin had the greatest number of cases reported (n=28) followed by saxagliptin (n=5), linagliptin (n=2), alogliptin (n=1), and vildagliptin (n=2).<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Postmarketing reports</b>: Hepatic enzyme elevations, fulminant hepatic failure<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity reactions (0.6%)</p>
<p><b>Postmarketing reports</b>: Anaphylaxis, angioedema, rash, urticaria, severe cutaneous adverse reactions (Stevens-Johnson syndrome)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Nasopharyngitis, upper respiratory tract infection<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Pruritus, rash</p>
<p><b>Postmarketing reports</b>: Exfoliative skin conditions including Stevens-Johnson syndrome, erythema multiforme, angioedema, urticaria</p>
<p></p>
<p>Dipeptidyl peptidase-4 inhibitors:</p>
<p><b>Postmarketing reports</b>: Bullous pemphigoid<sup>[Ref]</sup></p><p>Postmarketing reports of bullous pemphigoid requiring hospitalization have been reported with dipeptidyl peptidase-4 (DPP-4) inhibitors use.  These case typically recovered with topical or systemic immunosuppressive treatment and discontinuation of DPP-4 inhibitor.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hypoglycemia</p><p>Based on a pooled analysis the hypoglycemic risk of this drug was considered neutral.</p><h3>Cardiovascular</h3><p>In a clinical trial in patients with recent acute coronary syndrome, a greater proportion of patients receiving this drug were hospitalized for congestive heart failure compared with placebo (3.9% [n=106] vs 3.3% [n=89]),<sup>[Ref]</sup></p><p><b>Frequency not reported</b>: Heart failure<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. "Product Information. Nesina (alogliptin)." Takeda Pharmaceuticals America, Lincolnshire, IL. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. US Food and Drug Administration "FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM460038.pdf."   ([2015, Aug 28]):</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Nesina (alogliptin)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>4 Reviews</li>
<li>Drug class: dipeptidyl peptidase 4 inhibitors</li>
<li>FDA Alerts (3)</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Nesina &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Diabetes, Type 2</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to alogliptin: oral tablet</i></p><h3>General</h3><p>The most frequently reported side effects included nasopharyngitis, headache, and upper respiratory tract infection.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>During clinical trials, acute pancreatitis was reported in 6 (0.2%) patients receiving 25 mg and 2 patients (less than 0.1%) who were treated with active comparators or placebo.  In a cardiovascular outcome trial of patient with high cardiovascular risk, acute pancreatitis was reported in 10 patients receiving this drug and 7 patients receiving placebo (0.4% vs 0.3%).<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Abdominal pain, gastroesophageal reflux disease</p><p><b>Uncommon</b> (0.1% to 1%): Pancreatitis </p><p><b>Postmarketing reports</b>: Acute pancreatitis, diarrhea, constipation, nausea, ileus<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Frequency not reported</b>: Arthralgia<sup>[Ref]</sup></p><p>Between October 2006 and December 2013, thirty-three cases of severe arthralgia have been reported to the FDA Adverse Event Reporting System Database.  Each case involved the use of 1 or more dipeptidyl peptidase-4 (DPP-4) inhibitor.  In all cases, substantial reduction in prior activity level was reported, 10 patients were hospitalized due to disabling joint pain.  In 22 cases, symptoms appeared within 1 month of starting therapy, in 23 cases symptoms resolved less than 1 month after discontinuation.  A positive rechallenge was reported in 8 cases, with 6 cases involving use of a different DPP-4 inhibitor.  Sitagliptin had the greatest number of cases reported (n=28) followed by saxagliptin (n=5), linagliptin (n=2), alogliptin (n=1), and vildagliptin (n=2).<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Postmarketing reports</b>: Hepatic enzyme elevations, fulminant hepatic failure<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity reactions (0.6%)</p><p><b>Postmarketing reports</b>: Anaphylaxis, angioedema, rash, urticaria, severe cutaneous adverse reactions (Stevens-Johnson syndrome)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Nasopharyngitis, upper respiratory tract infection<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Pruritus, rash</p><p><b>Postmarketing reports</b>: Exfoliative skin conditions including Stevens-Johnson syndrome, erythema multiforme, angioedema, urticaria</p><p></p><p>Dipeptidyl peptidase-4 inhibitors:</p><p><b>Postmarketing reports</b>: Bullous pemphigoid<sup>[Ref]</sup></p><p>Postmarketing reports of bullous pemphigoid requiring hospitalization have been reported with dipeptidyl peptidase-4 (DPP-4) inhibitors use.  These case typically recovered with topical or systemic immunosuppressive treatment and discontinuation of DPP-4 inhibitor.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hypoglycemia</p><p>Based on a pooled analysis the hypoglycemic risk of this drug was considered neutral.</p><h3>Cardiovascular</h3><p>In a clinical trial in patients with recent acute coronary syndrome, a greater proportion of patients receiving this drug were hospitalized for congestive heart failure compared with placebo (3.9% [n=106] vs 3.3% [n=89]),<sup>[Ref]</sup></p><p><b>Frequency not reported</b>: Heart failure<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. "Product Information. Nesina (alogliptin)." Takeda Pharmaceuticals America, Lincolnshire, IL. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. US Food and Drug Administration "FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM460038.pdf."   ([2015, Aug 28]):</p><h2>More about Nesina (alogliptin)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>4 Reviews</li>
<li>Drug class: dipeptidyl peptidase 4 inhibitors</li>
<li>FDA Alerts (3)</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Nesina &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Diabetes, Type 2</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>